

Antibodies for medical research are brought to market

PROvendis closes contracts for three NRW universities

Research materials, like antibodies, are important in medical research. They are indispensable tools for scientists to understand the mechanisms and causes of disease. Through this understanding, research materials can lead to better therapeutic options. In 2018, PROvendis has out-licensed several monoclonal antibodies of various indications for research use. On behalf of the universities of Bonn, Duisburg-Essen and Cologne, PROvendis negotiated several contracts to successful closure of the deal. Licensees of the new antibodies are the company [Kerafast](#) in the USA and its British sister company [Absolute Antibody](#).

The antibodies were generated at the respective university hospitals. They are used in the research on Alzheimer's disease, cancer and rare genetic diseases. They include:

- [two monoclonal antibodies](#) against human CEACAM1 (University of Duisburg-Essen/UKF)
- one [monoclonal antibody](#) against human nitrosylated Amyloid beta (University of Bonn/UKB)
- [three monoclonal antibodies](#) against phosphorylated and non-phosphorylated Amyloid beta (University of Bonn/UKB)
- one monoclonal antibody against Nesprin2 (University of Cologne/UKK)

Kerafast is pleased to extend its portfolio with these specific antibodies. Since 2011, the company provides research material from over 180 scientific institutions worldwide. In 2018, Kerafast merged with Absolute Antibody with the aim to give researchers access to reagents and antibodies as well as recombinant antibody technology.

Under the new license agreements, scientists worldwide are now able to easily order and use these antibodies in their own research. In addition, using recombinant antibody technology, the antibodies will be engineered into new formats to help expand experimental possibilities and ensure reproducibility.